Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $6.38.

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, August 14th. Chardan Capital reiterated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Finally, Needham & Company LLC decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Monday, August 12th.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently bought and sold shares of the stock. Creative Planning bought a new position in shares of Taysha Gene Therapies in the third quarter valued at $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the second quarter valued at $48,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after buying an additional 17,446 shares in the last quarter. Scientech Research LLC bought a new position in shares of Taysha Gene Therapies in the second quarter valued at $97,000. Finally, SG Americas Securities LLC bought a new position in shares of Taysha Gene Therapies in the third quarter valued at $129,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Trading Up 7.9 %

NASDAQ TSHA traded up $0.10 on Wednesday, hitting $1.37. The company's stock had a trading volume of 9,396,881 shares, compared to its average volume of 2,391,842. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The company's 50-day moving average is $2.04 and its 200 day moving average is $2.42. The firm has a market cap of $280.77 million, a PE ratio of -6.75 and a beta of 0.44.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The firm had revenue of $1.11 million during the quarter, compared to analysts' expectations of $3.62 million. During the same period in the prior year, the company posted ($0.38) EPS. As a group, analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.